蛋白质酶抑制作为胸膜癌的潜在治疗标
Satoru Okada1,2, Louisa Benter1, Leon Schrell1
1Institute of Pathology, University Medical Center Göttingen, University of Göttingen, Göttingen, Germany.
Cell death & disease
|December 3, 2025
概括
胸膜瘤对蛋白质酶体抑制剂卡菲尔佐米布表现出敏感性,特别是表达免疫蛋白质酶体子单元的瘤. 与BCL2抑制剂的结合可能会降低胸腺瘤和胸腺癌治疗的毒性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 多模式放射化疗是不可切除的胸腺瘤 (TH) 和胸腺癌 (TC) 的标准.
- 罕见的胸膜瘤需要新的治疗策略.
- 胸膜上皮细胞表达多个蛋白质酶类,表明蛋白质酶抑制剂作为治疗途径.
研究的目的:
- 研究蛋白酶体抑制剂在TH和TC中的疗效.
- 与对卡菲尔佐米布的反应相关联免疫蛋白酶子单元表达.
- 探索协同作用的药物组合,以改善治疗结果.
主要方法:
- 在TH和TC细胞系上对120种细胞毒剂进行药物查.
- 患者样本的免疫组织化学和基因表达分析.
- 实验室功能研究,包括siRNA淘汰和药物协同作用测试.
主要成果:
- 胸腺癌细胞系对carfilzomib表现出极高的敏感性.
- 在50%的TC和许多TH中观察到免疫蛋白酶子单元 (β1i,β2i,β5i) 的显著表达.
- 卡菲尔佐米布与BCL2家族蛋白抑制剂产生协同作用,INF-γ治疗提高了敏感性.
结论:
- 胸膜癌和胸膜瘤是蛋白酶体抑制剂治疗的潜在候选者.
- 免疫蛋白酶表达水平可以预测对carfilzomib的反应.
- 组合疗法,如carfilzomib与BH3模仿剂,需要进一步研究以尽量减少毒性.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K


